Spots Global Cancer Trial Database for advanced malignant solid neoplasm

Every month we try and update this database with for advanced malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)	NCT04439344	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Binimetinib	18 Years -	National Cancer Institute (NCI)
Patient Considerations of Social Media Account Management After Death	NCT05035667	Advanced Malign... Hematopoietic a...	Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	NCT04439149	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	PI3K-beta Inhib...	18 Years -	National Cancer Institute (NCI)
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer	NCT05403580	Advanced Malign... Hematopoietic a...	Olanzapine Placebo Adminis... Questionnaire A...	18 Years -	Mayo Clinic
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer	NCT02227940	Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre...	Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological...	18 Years -	Roswell Park Cancer Institute
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	NCT04439318	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)	NCT04439240	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	FGFR Inhibitor ...	18 Years -	National Cancer Institute (NCI)
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)	NCT04439344	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Binimetinib	18 Years -	National Cancer Institute (NCI)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	NCT04491942	Advanced Bile D... Advanced Breast... Advanced Cervic... Advanced Endome... Advanced Esopha... Advanced Gastri... Advanced Head a... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Ovaria... Advanced Penile... Advanced Pleura... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Stage III Cervi... Stage III Dista... Stage III Intra... Stage III Lung ... Stage III Ovari... Stage III Penil... Stage III Pleur... Stage IV Cervic... Stage IV Distal... Stage IV Intrah... Stage IV Lung C... Stage IV Ovaria... Stage IV Penile... Stage IV Pleura... Triple-Negative... Unresectable Ur...	Cisplatin Elimusertib Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)	NCT06357988	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)	NCT04439123	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Capivasertib	18 Years -	National Cancer Institute (NCI)
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors	NCT01591356	Advanced Malign...	EphA2-targeting... Laboratory Biom... Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02408861	Advanced Malign... Anal Carcinoma HIV Infection Kaposi Sarcoma Lung Carcinoma Metastatic Mali... Recurrent Class... Refractory Clas... Unresectable So...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ipilimumab Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
FID-007 in Treating Participants With Advanced Solid Tumors	NCT03537690	Advanced Malign... Refractory Mali...	Laboratory Biom... PEOX-based Poly... Pharmacokinetic...	18 Years -	University of Southern California
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	NCT06320405	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Axatilimab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Paclitaxel Positron Emissi... Retifanlimab	18 Years -	OHSU Knight Cancer Institute
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study	NCT04552704	Advanced Malign...	CD24 Extracellu... Placebo Adminis...	18 Years -	University of California, Davis
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	NCT04439357	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	NCT05053971	Advanced Lympho... Advanced Malign... Advanced Pancre... B-Cell Non-Hodg... Metastatic Panc... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	BET Bromodomain... Core Biopsy Entinostat	18 Years -	National Cancer Institute (NCI)
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations	NCT01827384	Advanced Malign...	Adavosertib Carboplatin Everolimus Temozolomide Trametinib Veliparib	18 Years -	National Cancer Institute (NCI)
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	NCT03253679	Advanced Malign... Refractory Mali...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	NCT03872427	Advanced Malign... Metastatic Mali... NF1 Mutation Po... Unresectable Ma...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Pharmacodynamic... Positron Emissi... Telaglenastat H...	18 Years -	National Cancer Institute (NCI)
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)	NCT06390826	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib	18 Years -	National Cancer Institute (NCI)
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)	NCT04439175	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Taselisib	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	NCT04439149	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	PI3K-beta Inhib...	18 Years -	National Cancer Institute (NCI)
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer	NCT03927885	Advanced Malign... Metastatic Mali... Recurrent Malig...	Placebo Adminis... Quality-of-Life... Questionnaire A... Waiting List	18 Years -	M.D. Anderson Cancer Center
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies	NCT04678648	Advanced Malign... RAS Mutation Lung Cancer Colon Cancer Glioblastoma Pancreatic Canc...	RSC-1255 Dose E... RSC-1255 Dose E...	18 Years -	RasCal Therapeutics, Inc.
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)	NCT04439331	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Defactinib Hydr...	18 Years -	National Cancer Institute (NCI)
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer	NCT05403580	Advanced Malign... Hematopoietic a...	Olanzapine Placebo Adminis... Questionnaire A...	18 Years -	Mayo Clinic
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors	NCT01628640	Advanced Malign... Hepatocellular ...	Laboratory Biom... Pharmacological... Recombinant Ves...	18 Years -	Mayo Clinic
Studying TAK-243 in Patients With Advanced Cancer	NCT06223542	Advanced Lympho... Advanced Malign... Metastatic Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... UAE Inhibitor T...	18 Years -	National Cancer Institute (NCI)
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas	NCT03925428	Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Entinostat Molibresib	12 Years -	National Cancer Institute (NCI)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	NCT03218826	Advanced Breast... Advanced Malign... Advanced Prosta... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Metastatic Brea... Metastatic Mali... Metastatic Pros... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Triple-Negative... Unresectable So...	Docetaxel Laboratory Biom... Pharmacological... PI3Kbeta Inhibi...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors	NCT01628640	Advanced Malign... Hepatocellular ...	Laboratory Biom... Pharmacological... Recombinant Ves...	18 Years -	Mayo Clinic
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)	NCT04439201	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali...	Palbociclib	18 Years -	National Cancer Institute (NCI)
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	NCT04439279	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)	NCT04439240	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	FGFR Inhibitor ...	18 Years -	National Cancer Institute (NCI)
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)	NCT06400264	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab	18 Years -	National Cancer Institute (NCI)
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors	NCT05705492	Advanced Malign...	Biospecimen Col... Computed Tomogr... Olanzapine Placebo Adminis... Questionnaire A...	18 Years -	OHSU Knight Cancer Institute
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors	NCT03756818	Advanced Malign... Ovarian Carcino... Refractory Mali... Refractory Ovar...	Mivavotinib Paclitaxel Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)	NCT04439175	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Taselisib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer	NCT02451553	Advanced Malign... Bile Duct Carci... Recurrent Malig... Recurrent Pancr... Stage III Pancr... Stage IVA Pancr... Stage IVB Pancr...	Afatinib Dimale... Capecitabine Laboratory Biom...	19 Years -	University of Washington
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	NCT05455606	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Best Practice Chart Abstracti... Educational Int... Genomic Profile Interview Questionnaire A... Tumor Board Rev...	18 Years -	SWOG Cancer Research Network
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	NCT05733000	Advanced Biliar... Advanced Colore... Advanced Gastro... Advanced Lung A... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Urothe... Clinical Stage ... Clinical Stage ... Metastatic Bili... Metastatic Colo... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Metastatic Panc... Metastatic Urot... Refractory Bili... Refractory Colo... Refractory Gast... Refractory Lung... Refractory Ovar... Refractory Panc... Refractory Urot... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre...	Biospecimen Col... Computed Tomogr... Devimistat Fluorouracil Gemcitabine Hyd... Hydroxychloroqu... Magnetic Resona...	18 Years -	Northwestern University
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	NCT04511039	Advanced Malign... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Colo... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Trifluridine an... Talazoparib Tos...	18 Years -	Roswell Park Cancer Institute
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)	NCT05638295	Advanced Malign... Metastatic Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Panitumumab Sotorasib	18 Years -	National Cancer Institute (NCI)
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer	NCT05403580	Advanced Malign... Hematopoietic a...	Olanzapine Placebo Adminis... Questionnaire A...	18 Years -	Mayo Clinic
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)	NCT06400251	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	NCT05098405	Advanced Malign...	MP0317, a tri-s... MP0317, a tri-s...	18 Years -	Molecular Partners AG
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	NCT04693468	Advanced Malign... Metastatic Mali... Recurrent Malig...	Axitinib Crizotinib Palbociclib Ise... Talazoparib Tos...	18 Years -	M.D. Anderson Cancer Center
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	NCT03212274	Advanced Malign... Glioblastoma Recurrent Chola... Recurrent Gliom... Recurrent Malig... WHO Grade 2 Gli... WHO Grade 3 Gli...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)	NCT06360575	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	-	National Cancer Institute (NCI)
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)	NCT04439110	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trastuzumab Emt...	18 Years -	National Cancer Institute (NCI)
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)	NCT06308822	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors	NCT03784677	Advanced Malign... Refractory Mali... Refractory Ovar... Refractory Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IVA Ovari... Stage IVA Prost... Stage IVB Ovari... Stage IVB Prost...	TRPV6 Calcium C...	18 Years -	M.D. Anderson Cancer Center
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	NCT04439292	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Dabrafenib Mesy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: